Search Clinical Trials
Active, Not Recruiting
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (External Link)
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is …
Baylor Role:
Collaborator
Active, Not Recruiting
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma (External Link)
Because the cells have a new gene in them the patient will be followed for a total of 15 years to see if there are any long term side effects …
Baylor Role:
Lead Sponsor
Active, Not Recruiting
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (External Link)
The donor gave us blood to make CD19 chimeric receptor trivirus specific T cells in the laboratory. These cells were grown and frozen for the subject. To make these special …
Baylor Role:
Lead Sponsor